文献速递瓣膜病与结构性心脏病血脂与心血管预防

FOURIER 试验中 PCSK9 抑制剂与主动脉瓣狭窄的探索性分析

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.
PubMed 文献 · JAMA Cardiol · 2020-01-01

结果显示脂蛋白(a)升高与主动脉瓣狭窄事件风险增加相关,而校正脂蛋白(a)的 LDL-C 无显著关联;依洛尤单抗总体 HR 为 0.66,第一年后 HR 为 0.48,提示长期治疗可能减少主动脉瓣狭窄事件。

要点

  • 脂蛋白(a)每升高 1 个标准差,主动脉瓣狭窄事件调整后风险增加 55%。
  • 校正脂蛋白(a)的 LDL-C 与主动脉瓣狭窄事件无显著关联。

核心结论

  • 在 FOURIER 试验的探索性分析中,脂蛋白(a)水平升高而非校正脂蛋白(a)的 LDL-C 水平与后续主动脉瓣狭窄事件风险增加相关。
  • 长期依洛尤单抗治疗可能减少主动脉瓣狭窄事件,提示特异性降脂治疗或可预防或延缓主动脉瓣狭窄进展。

研究设计与样本

  • 患者按 1:1 随机分配至依洛尤单抗或安慰剂组,中位随访 2.2 年(四分位距 1.8-2.5 年)。

主要发现

  • 中位 2.2 年随访期间共发生 63 例主动脉瓣狭窄事件(48 例男性,占 76%;平均年龄 69 岁,标准差 9 岁)。
  • 依洛尤单抗组主动脉瓣狭窄事件总体风险比为 0.66(95%CI 0.40-1.09),治疗第一年风险比为 1.09(95%CI 0.48-2.47),第一年后风险比为 0.48(95%CI 0.25-0.93)。

临床怎么用

  • 对于动脉粥样硬化性心血管疾病患者,检测脂蛋白(a)水平可能有助于识别主动脉瓣狭窄事件高风险人群。
  • 依洛尤单抗长期治疗可能减少主动脉瓣狭窄事件,但该探索性发现需专门随机临床试验进一步验证。

局限性

  • 本分析为 FOURIER 试验的事后探索性分析,主动脉瓣狭窄事件为站点报告的不良事件,非预设终点。
  • 主动脉瓣狭窄事件数量较少(共 63 例),统计效能有限,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy. Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) have been implicated in the pathobiology of AS. The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab reduces circulating LDL-C concentrations by 50% to 60% and Lp(a) by 20% to 30%. OBJECTIVE: To determine whether evolocumab reduces the risk of AS events in patients with atherosclerotic cardiovascular disease. INTERVENTIONS: Patients were randomized 1:1 to evolocumab or placebo. DESIGN, SETTING, AND PARTICIPANTS: Exploratory analysis of the FOURIER trial, which enrolled 27 564 patients with stable atherosclerotic cardiovascular disease who were taking statin therapy at 1242 sites in 49 countries from February 2013 to November 2016. Patients were randomized to evolocumab or placebo and followed up for a median (interquartile range) of 2.2 (1.8-2.5) years. This post hoc analysis was performed from September 2019 to February 2020. MAIN OUTCOMES AND MEASURES: Site-reported adverse events of new or worsening AS or aortic valve replacement (termed AS events). The adjusted risk of AS events was calculated with a multivariable model including concentrations of Lp(a) and LDL-C corrected for Lp(a) content, plus age, sex, diabetes, hypertension, current smoking, and estimated glomerular filtration rate. Evolocumab efficacy was tested using a Cox proportional hazards model. RESULTS: Aortic stenosis events occurred in 63 patients (48 men [76%]; mean [SD] age, 69 [9] years) over a median of 2.2 years. Elevated Lp(a) concentration was associated with higher rates of AS events (adjusted hazard ratio [aHR], 1.55 [95% CI, 1.17-2.05] per SD; P = .002), including aortic valve replacement (aHR, 2.22 [95% CI, 1.38-3.58] per SD; P = .001), after multivariable adjustment. The corrected LDL-C concentration was not significantly associated with AS events (aHR, 1.23 [95% CI, 0.93-1.61] per SD; P = .14). The overall HR for AS events with evolocumab was 0.66 (95% CI, 0.40-1.09), with no apparent association in the first year (HR, 1.09 [95% CI, 0.48-2.47]) but an HR of 0.48 (95% CI, 0.25-0.93) after the first year of treatment. CONCLUSIONS AND RELEVANCE: In this exploratory analysis of the FOURIER trial, higher Lp(a) levels, but not Lp(a)-corrected LDL-C levels, were associated with a higher risk of subsequent AS events, including aortic valve replacement. Long-term therapy with evolocumab may reduce AS events, and this raises the possibility that specific pharmacologic lipid-lowering therapy could offer a means to prevent or slow the progression of AS. These exploratory findings merit further investigation with a dedicated randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01764633.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Bergmark BA, O'Donoghue ML, Murphy SA, et al. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiol. 2020. PMID: 32347887. doi:10.1001/jamacardio.2020.0728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。